InnovationRx is a weekly digest of healthcare news. To put it in your inbox, subscribe here.
T.he FDA approved the first vaccine for RSV, or respiratory syncytial virus, Wednesday, following a particularly tough 2022 season.Vaccine developed by Alex B. GlaxoSmithKlinewas approved for adults over the age of 60 who are susceptible to a highly contagious virus that can cause respiratory illness and lead to life-threatening pneumonia. , People with underlying diseases such as weakened immunity are at high risk of severe illness from RSV. Peter Markssaid the director of the FDA’s Center for Biologics Evaluation and Research in a statement.
of CDC RSV estimates that it leads to approximately 60,000 to 120,000 hospitalizations and 6,000 to 10,000 deaths annually among adults 65 years and older. A randomized controlled trial of 25,000 patients found that the vaccine reduced her risk of developing RSV-related respiratory infections by 82.6% and severe infections by 94.1%. The data are based on his one vaccination dose during one season, and the FDA says the study will continue to monitor the participant over his three seasons.
Apart from the elderly, a group particularly susceptible to RSV is children under the age of five. The CDC estimates that there are approximately 58,000 to 80,000 hospitalizations and 100 to 300 deaths each year within the group with RSV. Pfizer’s A vaccine that protects babies from RSV from birth by immunizing pregnant women received priority review from the FDA earlier this year. Here’s a roundup of the pharmaceutical companies competing to bring RSV vaccines to market.
Microsoft wants to use GPT-4 to automate medical notes, but doctors need convincing
An app called Dragon Ambient eXperience (DAX) records doctor-patient interactions and uses artificial intelligence to generate notes for medical records. It was developed by Nuance Communications. Microsoft is betting his $19 billion on the future of AI in healthcare. So far, human quality reviewers are checking his AI’s work before sending it to doctors for final review. The software giant hopes a fully automated version that generates notes in seconds will scale much faster than its predecessor. But can doctors relinquish control to imperfect machines and regain a few minutes of life? He said he might hesitate.
Please check this out for details.
Pipeline and deal updates
Reproductive Health: Morgan Health, a division of JPMorgan Chase, focused on improving the quality and cost of employer-sponsored healthcare, has invested $25 million in Kindbody. The $315 million-raised startup operates 32 fertility clinics and provides reproductive health benefits to big companies like Walmart and Medtronic.
Smart toilet: Casana, a startup developing smart toilet seats for in-home health monitoring, is FDA-cleared to measure heart rate and oxygen saturation on par with existing methods. Next, the company hopes to obtain approval to measure blood pressure, aiming to have the sheets on the market by the end of the year.
heart pump: Magenta Medical, which develops a small, foldable heart pump that is inserted through the groin without requiring invasive surgery, has raised $55 million, led by OrbiMed, to advance clinical research.
Microbiome Medicine: Last week, the FDA approved Vowst, an orally administered microbiome drug co-developed by Seres Therapeutics and Nestlé Health Science.This drug is approved for recurrent patients C. difficile Infection.
diagnose: Foresight Diagnostics, which develops cancer detection tests, has raised $58.75 million in Series B funding led by Foresite Capital.
Treatment of schizophrenia: The FDA has approved aripiprazole for the treatment of schizophrenia and bipolar disorder. It was jointly developed by Otsuka Pharmaceutical and Lundbeck under the brand name Abilify Asimtufii, and requires only one injection every two months.
AI Pharma Insights: ODAIA, which developed a SaaS platform that uses AI to power commercial insights that benefit pharmaceutical customers, has announced it has raised $25 million in Series B funding.
Opioid crisis worse than ever: Drug overdose deaths soar amid fentanyl surge
The Centers for Disease Control and Prevention reports that overdose deaths in the United States will soar in 2021, following years of increases that have pushed drug-related deaths to record levels. The surge in deaths from the synthetic opioid fentanyl is particularly alarming, increasing by almost a quarter (24%) compared to the previous year.
Please check this out for details.
Other healthcare news
CVS Health reported quarterly earnings of over $2 billion, supported by 1.1 million new Aetna Health Plan subscribers. The company also completed a $10.6 billion acquisition. oak street health This week includes a large network of doctor-staffed clinics used primarily by the elderly.
Eli Lilly seeks expedited approval from the FDA to approve diabetes drug Munjaro for weight loss following encouraging clinical trial results.
U.S. Surgeon General Vivek Marty Revealed his plan to tackle loneliness and social isolation as a public health crisis.
Studies combining two different cancer treatments, radiotherapy and immunotherapy, have shown early results in animals. pancreatic cancer, It is one of the leading causes of cancer death in humans.
all forbes
TikTok parent ByteDance’s ‘sensitive words’ tool monitors China, Trump, Uyghurs debate
The Kingdom of Bhutan Has Been Quietly Mining Bitcoin For Years
Trump Couldn’t See Inflation Coming — And It’s Costing Him More Than $1 Million A Month
what else i read
Will the COVID spring lull last? (Atlantic)
Women’s health research is underfunded – these charts show how (Nature)
Vermont removes residency requirement for medically assisted death (The New York Times)
